Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OLB vs KTTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KTTA Captures Overall Composite Edge (42.1 HOLD vs 48.6 HOLD), While OLB Leads 3–2 on Growth & Valuation Pillars

KTTA Overall Winner 6-Pillar Tally: OLB 3 – 2 KTTA (1 Tie) Matrix Metrics: OLB 3 – 5 KTTA

As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) captures the overall head-to-head institutional edge over The OLB Group, Inc. (OLB) on higher Unified Composite conviction (42.1/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Profitability & Quality), while OLB wins 3–2 across the 6-pillar growth and valuation breakdown. OLB trades at $0.12 (N/M Forward P/E, -73.3% operating margin) versus KTTA at $0.48 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While OLB currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. KTTA 42.1/100 HOLD), KTTA captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -73.3% operating margin) and revenue trajectory (+1498.1% vs. -43.6% YoY).
  • Technical & Structure Timing Caution: OLB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.6); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OLB vs KTTA
OLB NASDAQ
The OLB Group, Inc. Common Stock
Services-Business Services, Nec
$0.12
-4.33% 1D
Market Cap $3.8M
TTM Revenue $7.0M
Forward P/E N/M
Beta / 30D Vol 1.80β · 120% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 48.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.1%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $0.19 · SMA50: $0.27
KTTA NASDAQ Head-to-Head Winner
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
TTM Revenue $486,559
Forward P/E N/M
Beta / 30D Vol 0.68β · 185% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.1%) with fading momentum, RSI 50
RSI-14: 49.6 · SMA20: $0.48 · SMA50: $0.47

6-Pillar Scorecard Institutional Category Breakdown (OLB 3 – 2 KTTA)

Columns: Metric · OLB · KTTA
1. Valuation Multiples OLB
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.4x 36.3x
2. Growth & Scale KTTA
Revenue Growth (YoY) -43.6% +1498.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.0M $486,559
Market Cap $3.8M $17.7M
3. Profitability & Quality KTTA
Gross Margin -30.9% -0.5%
Operating Margin -73.3% 0.0%
Net Profit Margin -68.2% 0.0%
Return on Equity (ROE) -70.8% -88.8%
4. Balance Sheet & Cash Flow OLB
Cash Generation (TTM) -$2.6M -$18M
Cash Flow Margin -36.3% N/A
Net Cash / Leverage $1.1M Net Cash $1.31 Book/Sh · -88.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat OLB
OpEx & R&D Intensity 42.4% of Rev ($3.0M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Infrastructure Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OLB (3) vs KTTA (5)
Institutional Metric OLB KTTA Criterion Row Edge
Market Capitalization
Scale
$3.8M $17.7M Larger Scale KTTA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-43.6% +1498.1% Higher Growth KTTA
Operating Margin (TTM)
Profitability
-73.3% 0.0% Higher Margin KTTA
Net Profit Margin
Profitability
-68.2% 0.0% Higher Margin KTTA
Return on Equity (ROE)
Capital Efficiency
-70.8% -88.8% Higher ROE OLB
52-Week Range Position
Momentum
0% ($0–$2) 11% ($0–$2) Stronger Trend KTTA
Beta / 30D Volatility
Risk Regime
1.80β · 120% Vol 0.68β · 185% Vol Lower Realized Risk OLB
Unified Institutional Score
Composite Signal
48.6 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite OLB
Trailing 12M Revenue (USD)
Operating Scale
$7.0M $486,559 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-30.9% -0.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · 36.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.6M ($1.1M Net Cash) -$18M ($1.31 Book/Sh · -88.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KTTA +70.78 pp
OLB: -63.26% · KTTA: +7.52%
3M Horizon KTTA +56.13 pp
OLB: -61.34% · KTTA: -5.21%
6M Horizon KTTA +43.84 pp
OLB: -75.43% · KTTA: -31.59%
1Y Horizon KTTA +87.95 pp
OLB: -87.36% · KTTA: +0.59%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OLB Revenue KTTA Revenue OLB Op. Margin KTTA Op. Margin Margin Leader
FY2018 $10M N/A 5.9% N/A OLB
FY2019 $10M N/A -2.6% N/A OLB
FY2020 $10M N/A -7.5% N/A OLB
FY2021 $20M $0M -28.5% -29925.7% OLB
FY2022 $30M $0M -26.9% -2587.3% OLB
FY2023 $30M N/A -76.8% N/A OLB
FY2024 $10M N/A -90.9% N/A OLB
FY2025 $10M N/A -59.5% N/A OLB

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OLB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OLB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
KTTA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OLB Moat Profile Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
Competes within the Software - Infrastructure value chain with $3.8M market capitalization and -73.3% operating margin.
OpEx & R&D Reinvestment 42.4% of Rev ($3.0M)
90D Engineering Disclosures 0 Published
KTTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $17.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OLB vs KTTA Key Questions & Quantitative Answers

As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) captures the overall head-to-head institutional edge over The OLB Group, Inc. (OLB) on higher Unified Composite conviction (42.1/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Profitability & Quality), while OLB wins 3–2 across the 6-pillar growth and valuation breakdown. OLB trades at $0.12 (N/M Forward P/E, -73.3% operating margin) versus KTTA at $0.48 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OLB currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. KTTA 42.1/100 HOLD), KTTA captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -73.3% operating margin) and revenue trajectory (+1498.1% vs. -43.6% YoY). Technical & Structure Timing Caution: OLB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.6); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KTTA leads the Growth & Scale pillar: OLB posts -43.6% YoY revenue growth and +0.0% YoY earnings growth on $7.0M TTM revenue (-30.9% gross margin, -73.3% operating margin), compared with KTTA at +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OLB cumulative revenue shifted +0.0% while KTTA shifted N/A. In operating R&D and SG&A reinvestment, OLB deploys 42.4% of Rev ($3.0M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KTTA.

OLB screens cheaper on headline valuation multiples. OLB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-36.3% FCF margin), whereas KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OLB (-70.8% ROE) versus KTTA (-88.8% ROE) capital efficiency.

In options market volatility and institutional positioning, OLB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.80β · 120% Vol realized risk). By comparison, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.